The partnership agreement encompasses an equity investment and license agreement that grants Kanghui the exclusive right to manufacture and market Consensus’ joint implant products under both the Kanghui and Consensus brands in China and other select international territories.
The firms will also explore OEM opportunities, shared purchasing, and manufacturing collaborations to enhance product quality and reduce costs.
Upon closing of the partnership, Consensus will receive an equity investment from Kanghui and also will be eligible for royalties on commercial sales in the licensed territories.
Kanghui chief business officer Chen Yu said that with their existing distribution channels, formidable brand strength and marketing expertise in place, they believe that this differentiated joint product line will be a strong addition to Kanghui’s orthopedic business.
